MULTIPLE MYELOMA

Dr Shaji Kumar highlights bispecifics under development and how BCMA-targeting therapies impact patient selection for the treatment of R/R multiple myeloma.

Dr Shaji Kumar reviews key efficacy and safety outcomes of the updated data from MajesTEC-1, evaluating teclistamab in patients with R/R multiple myeloma.

Shaji Kumar, MD, presents a case of a 63-year-old woman with R/R multiple myeloma, shares his initial impression, and assess how clinical relapse impacts treatment decisions in patients with R/R multiple myeloma.

One of the most promising innovations in the multiple myeloma space has been the development of bispecific antibodies.

A 54-year-old woman received a diagnosis of Revised International Staging System stage II multiple myeloma. Marc J. Braunstein, MD, PhD discussed the case with a group of peers.

BCMA/CD19 dual-targeting FasTCAR-T cells showed a high objective response rate in a study of patients with newly diagnosed high-risk multiple myeloma.

Ciltacabtagene autoleucel continues to show promise for the treatment of relapsed or refractory multiple myeloma.

Results from MonumenTAL-1 presented during the 2022 ASH annual Meeting have led to the submission of a biologics license application for talquetamab.

In a final analysis of the DREAMM-2 study, results showed the rapid and durable responses of belantamab mafodotin continued in patients with relapsed/refractory multiple myeloma despite ocular toxicities.

Compared with standard of care regimens for triple-class exposed, relapsed or refractory multiple myeloma, belantamb mafodotin with pomalidomide and dexamethasone extended progression-free survival without sacrificing safety.

Rebecca Silbermann, MD, MMS, discusses the findings of the phase 2 GRIFFIN study which were presented at the 2022 ASH Annual Meeting.

Encouraging health-related quality of life benefit was demonstrated in for patients with transplant eligible, newly diagnosed multiple myeloma treated with a daratumumab quadruplet regimen.

In the CC-92480-MM-001, mezigdomide With dexamethasone demonstrated positive safety and efficacy in patients with heavily-pretreated multiple myeloma.

Positive results were reported on the phase 2 MagnetisMM-3 study at the ASH Annual Meeting 2022.

Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.

The use of 2 separate recommended phase 2 doses of Talquetamab was associated with high response rates in patients with heavily pre-treated relapsed/refractory multiple myeloma.

Based on the outcome of the confirmatory phase 3 OCEAN study, the FDA has requested melphalan flufenamide be withdrawn for patients with relapsed or refractory multiple myeloma.

Patients with multiple myeloma administered daratumumab in combination with bortezomib and dexamethasone demonstrated improvements in overall survival compared with those given bortezomib and dexamethasone alone.

Sagar Lonial, MD, FACP, provides a look at an upcoming Virtual Tumor Board program on BCMA-directed therapies in relapsed/refractory multiple myeloma treatment.

In an interview with Targeted Oncology, Christopher R. D’Angelo, MD discussed recent approvals in the multiple myeloma space and how to treat patients using immunotherapy.

At a live virtual event, Sumit Madan, MD, broke down the use of quadruplet therapies in the frontline setting for patients with multiple myeloma and how to care for patients when they relapse on treatment.

Thomas G. Martin, MD, discusses the goals and efficacy outcomes of the phase 1/2 MajesTEC-1 trial of teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.

During a Targeted Oncology case-based roundtable event, Yvonne A. Efebara, MD, MPH, discussed the role of triplet and quadruplet systemic therapies for newly diagnosed multiple myeloma and the use of autologous stem cell transplant.

After an update from the phase 3 DREAMM-3 study the use of belantamab monotherapy for previously treated patients with relapsed or refractory multiple myeloma was pulled from US market authorization by request of the FDA.

During a Targeted Oncology case-based roundtable event, Peter Forsberg, MD, discussed data from several trials of selinexor in patients with relapsed/refractory multiple myeloma.